The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 04, 2016

Filed:

Dec. 08, 2011
Applicants:

Marta Cosenza, Basel, CH;

Christoph Heusser, Oberwil, CH;

Julia Neugebauer, Munich, DE;

Eveline Schaadt, Munich, DE;

Stefanie Urlinger, Munich, DE;

Maximilian Woisetschlaeger, Oberwill, CH;

Inventors:

Marta Cosenza, Basel, CH;

Christoph Heusser, Oberwil, CH;

Julia Neugebauer, Munich, DE;

Eveline Schaadt, Munich, DE;

Stefanie Urlinger, Munich, DE;

Maximilian Woisetschlaeger, Oberwill, CH;

Assignee:

Novartis Pharma AG, Basel, CH;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); C07K 16/18 (2006.01); C07K 16/28 (2006.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 9/19 (2006.01); A61K 47/18 (2006.01); A61K 47/26 (2006.01); C07K 14/715 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2878 (2013.01); A61K 9/0019 (2013.01); A61K 9/08 (2013.01); A61K 9/19 (2013.01); A61K 39/39591 (2013.01); A61K 47/183 (2013.01); A61K 47/26 (2013.01); A61K 39/3955 (2013.01); A61K 39/39533 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01);
Abstract

Anti-BAFFR antibodies are formulated as lyophilisate or liquid formulation. The lyophilisates can be reconstituted to give a solution with a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The lyophilisate can be reconstituted with an aqueous reconstituent to provide an aqueous composition in which the antibody has a concentration of at least 50 mg/ml. The lyophilisate or aqueous pharmaceutical composition may include one or more of a sugar, a buffering agent, a surfactant, and/or a free amino acid.


Find Patent Forward Citations

Loading…